

Date: May 27, 2026

Ref. No.: KDL/SE/015/2026-27

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	--

Dear Sir/Madam,

Sub: Newspaper advertisement pertaining to the audited (Standalone and Consolidated) Financial Results for the quarter and year ended March 31, 2026.

Pursuant to Regulation 47 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of the newspaper advertisement pertaining to the audited (Standalone and Consolidated) Financial Results for the quarter and year ended March 31, 2026. The advertisements are published on May 27, 2026 in the following Newspapers:

1. Financial Express, English newspaper
2. Loksatta, Marathi newspaper

This will also be hosted on the Company's website at www.krsnaadiagnostics.com/investors

Request you to take the same on your records.

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above



KRSNAA DIAGNOSTICS LIMITED

Corporate Identity Number: L74900PN2010PLC138068

Registered and Corporate Office: S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station, Chinchwad, Taluka-Haveli, Pune - 411 019, Maharashtra.

Contact Person: Sujoy Sudipta Bose, Company Secretary and Compliance Officer

Telephone: +91 20 2740 2400; E-mail: investors@krsnaa.in; Website: www.krsnaadiagnostics.com

Extract of Audited Consolidated Financial Results for the Quarter And Year Ended March 31, 2026

(₹ in Million, except per share data)

Sl. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2026 (Refer Note 6)	December 31, 2025 (Un-audited)	March 31, 2025 (Refer Note 6)	March 31, 2026 (Audited)	March 31, 2025 (Audited)
1.	Total Income	2,241.03	1,849.69	1,904.64	8,161.64	7,426.95
2.	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	517.01	196.84	286.05	1,303.67	1,026.87
3.	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	517.01	196.84	286.05	1,303.67	1,026.87
4.	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	417.18	152.46	206.78	1,014.31	776.08
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	418.08	151.19	213.75	1,016.35	780.99
6.	Equity Share Capital	162.19	162.19	161.45	162.19	161.45
7.	Earnings Per Share (Face Value of ₹ 5/- each) (for continuing and discontinued operations)-(Not annualised for quarters)					
	1. Basic :	12.86	4.72	6.40	31.30	24.04
	2. Diluted :	12.70	4.66	6.28	30.88	23.56

Notes:

- These audited consolidated financial results ('consolidated financial results') of Krsnaa Diagnostics Limited ('the Holding Company') have been reviewed by the Audit Committee and approved by the Board of Directors on May 25, 2026.
- The above consolidated financial results have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
- Standalone information :

(₹ in Million)

Sl. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2026 (Refer Note 6)	December 31, 2025 (Un-audited)	March 31, 2025 (Refer Note 6)	March 31, 2026 (Audited)	March 31, 2025 (Audited)
a	Revenue from Operations	1,730.18	1,594.32	1,746.53	6,909.47	6,816.95
b	Profit Before Tax	541.32	212.22	292.13	1,323.21	1,096.02
c	Net Profit After Tax for the period/year	433.82	164.92	210.65	1,026.75	828.08
d	Other Comprehensive Income/(Losses)	(0.03)	(2.38)	5.76	(0.45)	3.76
e	Total Comprehensive Income	433.79	162.54	216.41	1,026.30	831.84

- The Group's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Group as one operating segment. Accordingly, the Group has single reportable segment and it derives entire revenue from the external customers in India and have entire assets located in India. The group has one major external customer which accounts for 10 per cent or more of groups revenues.
- Pursuant to search and seizure proceedings conducted under the provisions of section 132(1) and section 133A of the Income Tax Act, 1961 ("the search operations"), the Holding Company received assessment order dated March 31, 2024 for Assessment Year ("AY") AY 22-23. Further, Orders for AY 23-24, AY 21-22, AY 20-21 and AY 17-18 were received during the year ended March 31, 2025 and assessment orders for AY 2018-19 and AY 2019-20 were received on March 19, 2026 under the Income Tax Act, 1961 ("the Orders"). In the aforesaid Orders, the Income Tax authorities have made additions on account of undisclosed income and disallowance of certain deductions claimed by the Holding Company in the respective income tax returns filed for the relevant AY. Consequentially, it has resulted in a demand order of INR 626.90 million. The Holding Company has filed appeals against the aforesaid assessment Orders before the Joint Commissioner (Appeals)/Commissioner of Income- Tax (Appeals). Against the order for AY 2022-23, the Holding Company has deposited the tax under protest amounting to INR 39.27 million. Further, for the remaining AY's the Holding Company has requested to the Assistant Commissioner of Income Tax to adjust the income tax refunds for AY 2024-25 to the extent of INR 63.50 million against the amounts to be deposited under protest. These appeal applications have been acknowledged by the Commissioner of Income-Tax (Appeals). The Holding Company has provided the requisite disclosure to the stock exchange with respect to the search operations and receipt of the Orders in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 (as amended). The management of the Holding Company, based on available information and underlying evidence and opinion obtained from its tax consultants and experts, it of view that the aforesaid demand orders are not tenable and will not have any material impact on the Group's financial position as of March 31, 2026, and on its performance for the year ended on that date.
- The figures for quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between audited figures in respect of full financial year and published year to date unaudited figures up to the end of the third quarter, which were subject to limited review by the statutory auditors.
- During the quarter/year ended March 31, 2026, the Holding Company ceased to have significant influence over Apulki Healthcare Private Limited ("Investee"), consequent to fresh issue of shares by the investee Company and accordingly the investment has been derecognized as an associate. Consequent thereto, the retained investment is required to be fair valued in accordance with the requirement of IND AS 109 and has been fair valued based on valuation report from independent valuer. Holding Company has elected to recognise the resultant gain of INR. 259.52 million (net of deferred tax - INR. 222.41 million) through profit and loss account and accordingly has recognized and disclosed the gain under Other Income.
- The board of directors of the Holding Company have recommended the final dividend of Rs. 2.00 per equity share of the face value of Rs. 5 per equity share for the year ended March 31, 2026. The payment of dividend is subject to approval of shareholders at the ensuing Annual General meeting of the Holding company.
- Previous quarter/period figures have been regrouped/ rearranged wherever considered necessary.



On behalf of the Board of Directors
For Krsnaa Diagnostics Limited

Sd/-
Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Pune

Date: May 25, 2026



KRSNAA DIAGNOSTICS LIMITED

Corporate Identity Number: L74900PN2010PLC138068

Registered and Corporate Office: S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station, Chinchwad, Taluka-Haveli, Pune - 411 019, Maharashtra.

Contact Person: Sujoy Sudipta Bose, Company Secretary and Compliance Officer

Telephone: +91 20 2740 2400; E-mail: investors@krsnaa.in; Website: www.krsnaadiagnostics.com

Extract of Audited Consolidated Financial Results for the Quarter And Year Ended March 31, 2026

(₹ in Million, except per share data)

Sl. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2026 (Refer Note 6)	December 31, 2025 (Un-audited)	March 31, 2025 (Refer Note 6)	March 31, 2026 (Audited)	March 31, 2025 (Audited)
1.	Total Income	2,241.03	1,849.69	1,904.64	8,161.64	7,426.95
2.	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	517.01	196.84	286.05	1,303.67	1,026.87
3.	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	517.01	196.84	286.05	1,303.67	1,026.87
4.	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	417.18	152.46	206.78	1,014.31	776.08
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	418.08	151.19	213.75	1,016.35	780.99
6.	Equity Share Capital	162.19	162.19	161.45	162.19	161.45
7.	Earnings Per Share (Face Value of ₹ 5/- each) (for continuing and discontinued operations)-(Not annualised for quarters)					
	1. Basic :	12.86	4.72	6.40	31.30	24.04
	2. Diluted :	12.70	4.66	6.28	30.88	23.56

Notes:

- These audited consolidated financial results ('consolidated financial results') of Krsnaa Diagnostics Limited ('the Holding Company') have been reviewed by the Audit Committee and approved by the Board of Directors on May 25, 2026.
- The above consolidated financial results have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
- Standalone information :

(₹ in Million)

Sl. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2026 (Refer Note 6)	December 31, 2025 (Un-audited)	March 31, 2025 (Refer Note 6)	March 31, 2026 (Audited)	March 31, 2025 (Audited)
a	Revenue from Operations	1,730.18	1,594.32	1,746.53	6,909.47	6,816.95
b	Profit Before Tax	541.32	212.22	292.13	1,323.21	1,096.02
c	Net Profit After Tax for the period/year	433.82	164.92	210.65	1,026.75	828.08
d	Other Comprehensive Income/(Losses)	(0.03)	(2.38)	5.76	(0.45)	3.76
e	Total Comprehensive Income	433.79	162.54	216.41	1,026.30	831.84

- The Group's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Group as one operating segment. Accordingly, the Group has single reportable segment and it derives entire revenue from the external customers in India and have entire assets located in India. The group has one major external customer which accounts for 10 per cent or more of groups revenues.
- Pursuant to search and seizure proceedings conducted under the provisions of section 132(1) and section 133A of the Income Tax Act, 1961 ("the search operations"), the Holding Company received assessment order dated March 31, 2024 for Assessment Year ("AY") AY 22-23. Further, Orders for AY 23-24, AY 21- 22, AY 20-21 and AY 17-18 were received during the year ended March 31, 2025 and assessment orders for AY 2018-19 and AY 2019-20 were received on March 19, 2026 under the Income Tax Act, 1961 ("the Orders"). In the aforesaid Orders, the Income Tax authorities have made additions on account of undisclosed income and disallowance of certain deductions claimed by the Holding Company in the respective income tax returns filed for the relevant AY. Consequentially, it has resulted in a demand order of INR 626.90 million. The Holding Company has filed appeals against the aforesaid assessment Orders before the Joint Commissioner (Appeals)/Commissioner of Income- Tax (Appeals). Against the order for AY 2022-23, the Holding Company has deposited the tax under protest amounting to INR 39.27 million. Further, for the remaining AY's the Holding Company has requested to the Assistant Commissioner of Income Tax to adjust the income tax refunds for AY 2024-25 to the extent of INR 63.50 million against the amounts to be deposited under protest. These appeal applications have been acknowledged by the Commissioner of Income-Tax (Appeals). The Holding Company has provided the requisite disclosure to the stock exchange with respect to the search operations and receipt of the Orders in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 (as amended). The management of the Holding Company, based on available information and underlying evidence and opinion obtained from its tax consultants and experts, it of view that the aforesaid demand orders are not tenable and will not have any material impact on the Group's financial position as of March 31, 2026, and on its performance for the year ended on that date.
- The figures for quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between audited figures in respect of full financial year and published year to date unaudited figures up to the end of the third quarter, which were subject to limited review by the statutory auditors.
- During the quarter/year ended March 31, 2026, the Holding Company ceased to have significant influence over Apulki Healthcare Private Limited ("Investee"), consequent to fresh issue of shares by the investee Company and accordingly the investment has been derecognized as an associate. Consequent thereto, the retained investment is required to be fair valued in accordance with the requirement of IND AS 109 and has been fair valued based on valuation report from independent valuer. Holding Company has elected to recognise the resultant gain of INR. 259.52 million (net of deferred tax - INR. 222.41 million) through profit and loss account and accordingly has recognized and disclosed the gain under Other Income.
- The board of directors of the Holding Company have recommended the final dividend of Rs. 2.00 per equity share of the face value of Rs. 5 per equity share for the year ended March 31, 2026. The payment of dividend is subject to approval of shareholders at the ensuing Annual General meeting of the Holding company.
- Previous quarter/period figures have been regrouped/ rearranged wherever considered necessary.



On behalf of the Board of Directors
For Krsnaa Diagnostics Limited

Sd/-
Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Pune
Date: May 25, 2026

